Brainstorm Cell Therapeutics | BCLI - Selling And Administration Expenses


Brainstorm Cell Therapeutics reported $1.21M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Alterity Therapeutics Limited AUD 1.45M 703.96K Dec/2025
Biogen USD 709.7M 155.4M Jun/2026
Brainstorm Cell Therapeutics USD 1.21M 178K Mar/2026
Cipla INR 13.25B 101.8M Dec/2025
Clal Biotechnology ILS 3.31M 513K Dec/2022
Compugen USD 2.43M 222K Mar/2026
CSL USD 1.23B 498M Dec/2025
Cytokinetics USD 104.4M 499K Jun/2026
Gilead Sciences USD 1.52B 70M Jun/2026
Grifols EUR 320.45M 12.65M Dec/2025
Halozyme Therapeutics USD 57M 10.71M Jun/2026
Mesoblast USD 85.89M 57.35M Jun/2026